Ubs Group Ag Ardelyx, Inc. Transaction History

Ubs Group Ag

  • $528 Billion
  • Q1 2025

A detailed history of Ubs Group Ag transactions in Ardelyx, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 821,191 shares of ARDX stock, worth $3.29 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
821,191
Previous 714,764 14.89%
Holding current value
$3.29 Million
Previous $3.7 Million 9.12%
% of portfolio
0.0%
Previous 0.0%

Shares

32 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 13, 2025
BUY
$4.91 - $6.36 $522,556 - $676,875
106,427 Added 14.89%
821,191 $4.03 Million
Q4 2024

Feb 14, 2025
BUY
$4.49 - $6.85 $863,615 - $1.32 Million
192,342 Added 36.82%
714,764 $3.7 Million
Q3 2024

Nov 14, 2024
BUY
$5.28 - $7.57 $253,360 - $363,246
47,985 Added 10.11%
522,422 $3.6 Million
Q2 2024

Aug 13, 2024
SELL
$5.89 - $9.31 $2.42 Million - $3.82 Million
-410,066 Reduced 46.36%
474,437 $3.52 Million
Q1 2024

May 13, 2024
BUY
$6.05 - $9.74 $1.73 Million - $2.78 Million
285,853 Added 47.75%
884,503 $6.46 Million
Q4 2023

Feb 09, 2024
BUY
$3.29 - $6.64 $1.24 Million - $2.5 Million
376,294 Added 169.23%
598,650 $3.71 Million
Q3 2023

Nov 09, 2023
SELL
$3.3 - $4.83 $1.2 Million - $1.76 Million
-363,759 Reduced 62.06%
222,356 $907,000
Q2 2023

Aug 11, 2023
BUY
$3.23 - $4.95 $26,056 - $39,931
8,067 Added 1.4%
586,115 $1.99 Million
Q1 2023

May 12, 2023
BUY
$2.68 - $4.79 $1.21 Million - $2.16 Million
450,996 Added 354.97%
578,048 $2.77 Million
Q4 2022

Feb 08, 2023
BUY
$1.22 - $2.85 $149,147 - $348,418
122,252 Added 2546.92%
127,052 $362,000
Q2 2022

Aug 10, 2022
SELL
$0.51 - $1.17 $52 - $120
-103 Reduced 2.1%
4,800 $3,000
Q1 2022

May 16, 2022
SELL
$0.65 - $1.18 $19,812 - $35,967
-30,481 Reduced 86.14%
4,903 $5,000
Q4 2021

Feb 14, 2022
BUY
$0.86 - $1.7 $23,804 - $47,056
27,680 Added 359.29%
35,384 $39,000
Q3 2021

Nov 15, 2021
SELL
$1.27 - $8.17 $51,341 - $330,280
-40,426 Reduced 83.99%
7,704 $10,000
Q2 2021

Aug 13, 2021
SELL
$6.55 - $8.98 $322,076 - $441,564
-49,172 Reduced 50.54%
48,130 $365,000
Q1 2021

May 12, 2021
BUY
$6.1 - $7.69 $515,431 - $649,781
84,497 Added 659.88%
97,302 $644,000
Q4 2020

Feb 11, 2021
BUY
$5.05 - $7.1 $1,757 - $2,470
348 Added 2.79%
12,805 $83,000
Q3 2020

Nov 12, 2020
BUY
$5.25 - $7.08 $2,467 - $3,327
470 Added 3.92%
12,457 $66,000
Q2 2020

Jul 31, 2020
SELL
$5.37 - $8.11 $98,351 - $148,534
-18,315 Reduced 60.44%
11,987 $83,000
Q1 2020

May 01, 2020
SELL
$4.35 - $8.79 $81,632 - $164,953
-18,766 Reduced 38.24%
30,302 $172,000
Q4 2019

Feb 14, 2020
BUY
$4.23 - $8.29 $51,614 - $101,154
12,202 Added 33.1%
49,068 $368,000
Q3 2019

Nov 14, 2019
BUY
$2.15 - $6.28 $51,342 - $149,966
23,880 Added 183.89%
36,866 $173,000
Q2 2019

Aug 14, 2019
BUY
$2.49 - $3.73 $24,865 - $37,247
9,986 Added 332.87%
12,986 $35,000
Q1 2019

May 14, 2019
SELL
$1.88 - $3.35 $31,952 - $56,936
-16,996 Reduced 85.0%
3,000 $8,000
Q4 2018

Feb 14, 2019
BUY
$1.66 - $4.16 $27,200 - $68,165
16,386 Added 453.91%
19,996 $35,000
Q3 2018

Nov 14, 2018
SELL
$3.75 - $4.65 $4,462 - $5,533
-1,190 Reduced 24.79%
3,610 $16,000
Q2 2018

Aug 14, 2018
SELL
$3.7 - $5.8 $18,500 - $29,000
-5,000 Reduced 51.02%
4,800 $18,000
Q1 2018

May 15, 2018
SELL
$5.05 - $7.9 $4,040 - $6,320
-800 Reduced 7.55%
9,800 $49,000
Q4 2017

Feb 14, 2018
SELL
$4.85 - $7.8 $6,363 - $10,233
-1,312 Reduced 11.01%
10,600 $70,000
Q3 2017

Nov 14, 2017
BUY
$4.35 - $5.7 $16,717 - $21,905
3,843 Added 47.63%
11,912 $67,000
Q2 2017

Aug 14, 2017
BUY
N/A
5,155 Added 176.9%
8,069 $41,000
Q1 2017

Nov 14, 2017
BUY
N/A
2,914
2,914 $36,000

Others Institutions Holding ARDX

# of Institutions
235
Shares Held
166M
Call Options Held
490K
Put Options Held
2.35M
View Full List

About ARDELYX, INC.

ARDX Quotes by TradingView
  • Ticker ARDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 154,636,000
  • Market Cap $620M
  • Description
  • Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...
More about ARDX
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email